Skip to content

AETERNUM HEALTH, INC.: 10-Q filed 2025-08-19

What AETERNUM HEALTH, INC. reported in its quarterly report filed 2025-08-19 (fiscal Q2 2025): 29 published measures, 86 facts as tagged in accession 0001641172-25-024714.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-19
Fiscal period
fiscal Q2 2025
Accession
0001641172-25-024714 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AETERNUM HEALTH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-30144,983USD
At 2024-12-3165,417USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-301,906,739USD
At 2024-12-311,741,439USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-30-1,761,756USD
At 2025-03-31-1,655,901USD
At 2024-12-31-1,676,022USD
At 2024-06-30-1,459,514USD
At 2024-03-31-1,343,231USD
At 2023-12-31-1,225,704USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-06-300USD
At 2024-12-310USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-105,855USD91
2025-01-01 to 2025-06-30-99,964USD181
2025-01-01 to 2025-03-315,891USD90
2024-04-01 to 2024-06-30-116,283USD91
2024-01-01 to 2024-06-30-233,810USD182
2024-01-01 to 2024-03-31-117,527USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-71USD181
2024-01-01 to 2024-06-30-145,012USD182

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-04-01 to 2025-06-307,122USD91
2025-01-01 to 2025-06-30171,779USD181
2024-04-01 to 2024-06-3033,361USD91
2024-01-01 to 2024-06-3037,199USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-305,000USD181
2024-01-01 to 2024-06-30-89,400USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-3,041,011USD
At 2024-12-31-2,941,047USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-04-01 to 2025-06-3049,190,204shares91
2025-01-01 to 2025-06-3048,903,235shares181
2024-04-01 to 2024-06-3048,478,678shares91
2024-01-01 to 2024-06-3048,478,678shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-3049,190,204shares91
2025-01-01 to 2025-06-3048,903,235shares181
2024-04-01 to 2024-06-3048,478,678shares91
2024-01-01 to 2024-06-3048,478,678shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300USD/shares181
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300USD/shares181
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-3014,230USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-88,710USD91
2025-01-01 to 2025-06-30-65,978USD181
2024-04-01 to 2024-06-30-92,628USD91
2024-01-01 to 2024-06-30-198,008USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-30143,983USD
At 2024-12-3164,417USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-30987,060USD
At 2024-12-31821,761USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-06-30101,717USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-3083,068USD91
2025-01-01 to 2025-06-30185,688USD181
2024-04-01 to 2024-06-30125,140USD91
2024-01-01 to 2024-06-30221,714USD182

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-06-3019,005USD
At 2024-12-3144,763USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-5,642USD91
2025-01-01 to 2025-06-30119,710USD181
2024-04-01 to 2024-06-3032,512USD91
2024-01-01 to 2024-06-3023,706USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-3049,190,204shares
At 2024-12-3148,478,678shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-30809,807USD
At 2024-12-31802,692USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-06-301,000USD
At 2024-12-311,000USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-3014,833USD91
2025-01-01 to 2025-06-3040,528USD181
2024-04-01 to 2024-06-3034,239USD91
2024-01-01 to 2024-06-3055,842USD182

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-04-01 to 2025-06-3017,145USD91
2025-01-01 to 2025-06-3033,986USD181
2024-04-01 to 2024-06-3023,655USD91
2024-01-01 to 2024-06-3035,802USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-17,145USD91
2025-01-01 to 2025-06-30-33,986USD181
2024-04-01 to 2024-06-30-23,655USD91
2024-01-01 to 2024-06-30-35,802USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30101,717USD181
2024-01-01 to 2024-06-3014,385USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-25,758USD181
2024-01-01 to 2024-06-3011,345USD182

Inspect the source

Entity
AETERNUM HEALTH, INC. / CIK 0000764630
Captured
2026-09-19T15:02:38.824Z
SEC response SHA-256
6c9d70d4b82a4edc5f4de8082c897762179c66ba1d127e497154b6262edf21b8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000764630.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))